An interventional study of tele-visit in Obstructive Sleep Apnea, sponsored by AGIR à Dom. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by AGIR à Dom · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 201 studies in Sleep Apnea, Obstructive with a site in France — 39 open to participants now, 48 under way, 4 of them phase 3. Sleep Apnea, Obstructive · France.
Among the 201 studies in Sleep Apnea, Obstructive with a site in France, this one is the 13th largest by enrollment of the 133 interventional ones that give a count, is one of 8 that started in 2023, is one of 105 with no phase, reaches primary completion later than 13 of the 47 other live ones, and was the 160th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →39 of the 201 studies in Sleep Apnea, Obstructive with a site in France are open now. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18–75
Hospices Civils de Lyon · Sites in France
Ages 4–17
University Hospital, Grenoble · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–84
Hospices Civils de Lyon · Sites in France
Ages 5 mo–6 mo
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
201 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 320 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 52 across the 133 interventional studies, 140 across the 67 observational. Of the 121 that completed or were terminated, 6 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 201 have an industry lead sponsor. The 10 most frequent:
AGIR à Dom is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
AGIR à Dom has 5 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
13 of the studies in Sleep Apnea, Obstructive with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07283289Centre Hospitalier Intercommunal de Toulon La Seyne sur MerPrevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease | 2026-11 |
| NCT05939934University Hospital, AngersImpact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal | 2026-11 |
| NCT07792746Clinique du MillenaireSleep Apnea Biomarkers and Adherence to Continuous Positive Airway Pressure | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 201 studies in Sleep Apnea, Obstructive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the impact of telecare on continous positive airway pressure (CPAP) patients follow up by home care provider (HCP)
Obstructive sleep apnea (OSA) syndrome is a chronic respiratory pathology affecting 4% of french adult population and reference treatment for moderate to severe forms of obstructive sleep apnea syndrome (OSA) is continuous positive airway pressure (CPAP).
However, CPAP treatment is binding, so nearly a quarter of patients abandoning treatment at 1 year and nearly half of them at 3 years. Support for these patients on CPAP must therefore be optimal and seek patient satisfaction; HCP (Home Care Provider) plays an important role in this follow-up.
Since 2018 in France, teleconsultation entered on common law but was little used. The pandemic has disrupted the habits of care and patients monitoring by developing remote monitoring. Home Care Providers (HCP) have also been forced to organize remote monitoring, particularly for the annual follow-up visit (technical tele-visit).
The impact of the annual follow-up visits of HCP by tele-visit has never been clinically evaluated. If its clinical relevance were demonstrated and patient satisfaction confirmed, this follow-up modality could become, like telecare, a new standard for the follow-up of patients on CPAP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receive a annual CPAP remote visit by HCP technician, then home visit the following year
Procedure: tele-visit
Standard care : patients receive an annual CPAP home visit by HCP technician
The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
To compare CPAP compliance between the two management modalities
CPAP mean compliance between intervention and control groups, adjusted for the three months prior to inclusion : in hours/day, collected on the CPAP remote monitoring report
Time frame: Over the 3 months (tele)visit follow-up
To compare overall patient satisfaction between the two management modalities
The Consumer Satisfaction Questionnaire (CSQ-8) mean score between intervention and control groups, after the CPAP (tele-)visit follow-up . The overall score is calculated by adding the respondent's evaluation score (item evaluation) for each item on the scale. For the CSQ-8 version, the scores therefore range from 8 to 32, with higher values indicating greater satisfaction.
Time frame: Immediately after the (tele-)visit follow-up
To compare the impact on daytime sleepiness between the two management modalities
Epworth Sleepiness Scale (ESS) mean score between intervention and control group. All items are assumed to be integers (0-3). The ESS score is the sum of 8 item scores. 0-10 = normal range of sleepiness in healthy adults 11 to 14 = mild sleepiness 15 to 17 = moderate sleepiness 18 to 24 = severe sleepiness
Time frame: At 3 months after (tele-)visit follow-up
To compare impact on quality of life between the two management modalities
The EuroQol 5 Dimensions - 5 levels (EQ5D-5L) questionnaire mean score between intervention and control group, adjusted on the baseline score. it's composed of two parts : A visual analog scale (20 cm line, graduated from 0 to 100 where patient indicates his or her current state of health, 0 being the worst and 100 the best) the completion of 5 items evaluating mobility, autonomy, daily activities, pain or discomfort and anxiety or depression. 1. indicating no problem 2. indicating slight problems 3. indicating moderate problems 4. indicating severe problems 5. indicating unable to/extreme problems Each state is referred to by a 5-digit code.
Time frame: At 3 months after (tele-)visit follow-up
To compare CPAP compliance in medium term between the two management modalities
CPAP mean compliance between intervention and control group : in hours/day, collected on the CPAP remote monitoring report
Time frame: Over the 12 months (tele)visit follow-up
To compare impact on CPAP continuation between the two management modalities
Rate of CPAP removal between intervention and control group ; the number of CPAP unbundling among participants
Time frame: Over the 12 months (tele)visit follow-up
To compare treatment effectiveness between the two management modalities
Apnea Hypopnea Index (AHI) mean between intervention and control group. AHI corresponds to the number of apneas and hypopneas per hour of sleep, collected on the CPAP remote monitoring report.
Time frame: Over the 12 months (tele)visit follow-up
To compare treatment quality on mask leakage between the two management modalities
Leakage mean level between intervention and control group
Time frame: Over the 3 months (tele)visit follow-up
To compare occurrence frequency of CPAP-related adverse effect(s) between the two management modalities
The Side-Effects to CPAP treatment Inventory (SECI) mean score between the intervention and control group. Each of the 15 items relating to side effects associated with CPAP treatment has three subscales: frequency, breadth of the side effect, and impact on CPAP use. For each subscale, the patient will complete a five-point Likert-type scale, so the possible range for each subscale is 15 to 75. A higher score indicates greater frequency of side effects, greater breadth of side effects, and greater intensity of side effects.
Time frame: Over the 3 months (tele)visit follow-up
To compare follow-up impact in addition to the annual visit between the two management modalities
Mean number of calls and visits made per patient between control and intervention group
Time frame: Over the 12 months (tele)visit follow-up
To evaluate failed visits number between the two care modalities
Mean number of (tele-)visits requiring a reprogramming (absence, technical problem, last minute deprogramming, home visit...)
Time frame: Over the 12 months (tele)visit follow-up
To evaluate patient satisfaction with tele-visits
The Televisit Satisfaction Questionnaire (TSQ) mean score 14 items, rated between 1 and 5 by the patient. The sum of the items corresponds to a score ranging from 14 to 70.
Time frame: Immediately after the (tele-)visit follow-up
To evaluate technician satisfaction with tele-visits
The Televisit Satisfaction Questionnaire (TSQ) questionnaire mean score 14 items, rated between 1 and 5 by the patient. The sum of the items corresponds to a score ranging from 14 to 70.
Time frame: Immediately after the (tele-)visit follow-up
Comparison of the environmental impact associated with the two patient follow-up methods (home visit versus tele-visit)
Comparison of the carbon emissions generated by each care modality, calculated over the entire patient participation period and expressed in kgCO₂e, considering only the impact of the follow-up method itself, without including the individual use of the CPAP device.
Time frame: Over the 12 months (tele)visit follow-up
To evaluate patient overall satisfaction regarding clinical study participation
Survey Satisfaction
Time frame: Over the 3 months (tele)visit follow-up
Started Apr 2023 (actual). Primary completion is estimated for May 2026, 37 months after the start.
Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 37 months is above that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AGIR à Dom